Skip to main content


Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

These stocks have had a really good run, says Wedbush Securities, which is holding its annual health care investment conference in New York.

Teva Makes $40.1B Bid for Generic-Drug Rival Mylan, Proving Rumors Right

Israeli generic-drug giant Teva announces it aims to acquire competitor Mylan for $82 per share, or $40.1 billion.

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Mylan's deal to buy Perrigo is taking another potential target off the block.

Teva, Actavis, Other Giants Set to Battle for Generics Space

Teva, Actavis and other generics giants may start preying on each other.

George Soros Might Invest $1 Billion in Ukraine -- Here's Where Else He's Investing

George Soros said this week that he is ready to pour $1 billion in Ukraine. With a $24 billion personal fortune, he can certainly afford it.

Breaking News

Elon Musk Says Only Two Things Could Make Him Leave Tesla

Tesla CEO Musk discusses succession plans and Twitter with shareholders.

Caesars Inches Closer to Huge Las Vegas Strip Move

The company has made clear what it plans on the Las Vegas Strip, but it has a fast-approaching deadline.

Elon Musk Has Bad News About Tesla's Cybertruck

Long-delayed futuristic looking electric vehicle will be in production by the middle of 2023